SUTIB, the generic version of Sunitinib oral capsules, has been launched by Glenmark Pharmaceuticals to treat kidney cancer in India. Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumours and advanced renal cell carcinoma. It is also approved for patients with a certain type of Pancreatic Neuroendocrine Tumours.
For over a decade, Sunitinib has been well recognized as one of the ‘gold-standard’ of care in cases of fast-spreading (metastatic) renal cancer. Research shows that Sunitinib alone has helped reduce the risk of progression of renal cancer by 58%. The drug is launched at an MRP that is approx. 96% lower than the MRP compared to the innovator brand, priced at Rs. 7000 (50 mg), Rs. 3600 (25 mg) and Rs. 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration. “Oncology is an important focus area for Glenmark. Glenmark is committed to bringing targeted and effective medicines at an affordable cost to physicians and their patients”, said Mr. Alok Malik, Group Vice-President & Business Head, India Formulations.
